StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) company profile

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.36−0.02 (-6.17%)

Close on Nov 17, 2026Market cap $4.67MP/E –Yield –

About Lantern Pharma

Pharmaceutical Preparations, SIC 2834

Lantern Pharma Inc. is an artificial intelligence-focused biotechnology company dedicated to developing targeted cancer therapies. The company operates a proprietary machine learning and big data analytics platform called RADR to identify biologically relevant genomic signatures, discover drug candidates, and match therapies with specific cancer patient populations likely to respond. Its clinical-stage portfolio focuses on small molecule oncology candidates, including lead programs LP-300, LP-184, and LP-284, addressing solid tumors and blood cancers. Additionally, the company advances an antibody-drug conjugate development program, an AI platform named withZeta.ai for rare cancer research, and central nervous system oncology candidates through its subsidiary, Starlight Therapeutics.

The company maintains its principal executive offices in Dallas, Texas. Its operations incorporate clinical programs evaluating therapies across several indications, such as triple-negative breast cancer and non-small cell lung cancer. The text does not provide details on foreign facilities, physical operating locations, or store counts.

Summary of the business section of Lantern Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Lantern Pharma Inc.
Headquarters
Dallas, TX
Address
1920 Mckinney Avenue, 7th Floor 75201
Phone
(972) 277-1136
Employees
16, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Texas
Fiscal year ends
December 31
Auditor
EisnerAmper LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
LTRN
Exchange
Nasdaq
IPO date
Jun 12, 2020
Shares outstanding
13M, Aug 10, 2026
Public float
$33.94M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1763950
CUSIP
51654W101
ISIN
US51654W1018
FIGI
BBG00GM6LK17
Share class FIGI
BBG00GM6LK26
EIN
46-3973463

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Panna SharmaPresident & CEO, Director–
Kishor G. BhatiaChief Scientific Officer–
David R. MargraveChief Financial Officer–
Lee Troy SchalopDirector48,544
D. Jeffrey KeyserDirector94,303
David S. SilbersteinDirector1,044,000
Vijay ChandruDirector–
Maria-Luisa MaccecchiniDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$763.75K$778.96K$415.00K$71–
FY2024$1.09M$1.02M$646.00K$75–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Panna Sharma
Chief Executive Officer and President
$575.00K$178.25K–$10.50K$763.75K-30%
David R. Margrave
Chief Financial Officer and Secretary
$413.80K$116.48K$44.80K$10.50K$585.58K-22%
Kishor Bhatia
Chief Scientific Officer
$189.60K$26.74K$22.40K$5.69K$244.42K-55%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 12, 2020
Offer price
$15.00
Securities offered
1,750,000
Gross proceeds
$26.25M
Exchange
Nasdaq
First trading day
Jun 11, 2020
First-day close
$14.95-0.3%
Lock-up ends (est.)
Dec 8, 2020

“We are offering 1,750,000 shares of our common stock at an initial public offering price of $15.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of the date of this report, we employ a total of 16 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 1, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 12, 2020IPOInitial public offering priced (424B4 prospectus)
Jun 8, 2020ListingRegistration of securities on an exchange (Form 8-A)
Jan 14, 2019Name changeName changed from Lantern Pharma to Lantern Pharma Inc.

See a number that looks wrong?